How much revenue did Amicus Therapeutics generate this year?
Amicus Therapeutics has achieved a revenue of 520.38 M USD this year.
Amicus Therapeutics Revenue 2024
Amicus Therapeutics Revenue
520.38 M USD
Ticker
FOLD
ISIN
US03152W1099
WKN
A0MSMZ
In 2024, Amicus Therapeutics's sales reached 520.38 M USD, a 30.3% difference from the 399.36 M USD sales recorded in the previous year.
The Amicus Therapeutics Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2030e | 1.28 | 28,17 |
| 2029e | 1.56 | 23,18 |
| 2028e | 1.37 | 26,39 |
| 2027e | 1.14 | 31,87 |
| 2026e | 0.87 | 41,79 |
| 2025e | 0.66 | 55,21 |
| 2024e | 0.52 | 69,57 |
| 2023 | 0.4 | 90,65 |
| 2022 | 0.33 | 88,27 |
| 2021 | 0.31 | 88,71 |
| 2020 | 0.26 | 88,08 |
| 2019 | 0.18 | 87,98 |
| 2018 | 0.09 | 84,21 |
| 2017 | 0.04 | 83,20 |
| 2016 | 0.01 | 82,00 |
| 2015 | - | - |
| 2014 | 0 | 30169,17 |
| 2013 | 0 | 90507,50 |
| 2012 | 0.02 | 1967,55 |
| 2011 | 0.02 | 1691,73 |
| 2010 | 0 | 40225,56 |
| 2009 | 0.06 | 562,16 |
| 2008 | 0.02 | 2413,53 |
| 2007 | 0 | 20112,78 |
| 2006 | - | - |
| 2005 | - | - |
| 2004 | - | - |
Amicus Therapeutics Revenue, EBIT, Net Income US03152W1099 · A0MSMZ
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Amicus Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Amicus Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Amicus Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Amicus Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Amicus Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Amicus Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Amicus Therapeutics’s growth potential.
Amicus Therapeutics Revenue, Profit, and EBIT History
| Date | Amicus Therapeutics Revenue | Amicus Therapeutics EBIT | Amicus Therapeutics Net Income |
|---|---|---|---|
| 2030e | 1.28 B undefined | 829.46 M undefined | 664.67 M undefined |
| 2029e | 1.56 B undefined | 749.43 M undefined | 731.14 M undefined |
| 2028e | 1.37 B undefined | 771.43 M undefined | 655.61 M undefined |
| 2027e | 1.14 B undefined | 567.27 M undefined | 462.25 M undefined |
| 2026e | 866.27 M undefined | 273.53 M undefined | 229.61 M undefined |
| 2025e | 655.7 M undefined | 110.55 M undefined | 72.85 M undefined |
| 2024e | 520.38 M undefined | -13.69 M undefined | -63.75 M undefined |
| 2023 | 399.36 M undefined | -76.08 M undefined | -151.58 M undefined |
| 2022 | 329.2 M undefined | -205.5 M undefined | -236.6 M undefined |
| 2021 | 305.5 M undefined | -206.4 M undefined | -250.5 M undefined |
| 2020 | 260.9 M undefined | -247 M undefined | -276.9 M undefined |
| 2019 | 182.2 M undefined | -304.1 M undefined | -356.4 M undefined |
| 2018 | 91.2 M undefined | -328.8 M undefined | -349 M undefined |
| 2017 | 36.9 M undefined | 23.4 M undefined | -284 M undefined |
| 2016 | 5 M undefined | -181.8 M undefined | -200 M undefined |
| 2015 | 0 undefined | -130.4 M undefined | -132.1 M undefined |
| 2014 | 1.2 M undefined | -68.8 M undefined | -68.9 M undefined |
| 2013 | 400,000 undefined | -61.7 M undefined | -59.6 M undefined |
| 2012 | 18.4 M undefined | -52.9 M undefined | -48.8 M undefined |
| 2011 | 21.4 M undefined | -50.9 M undefined | -44.4 M undefined |
| 2010 | 900,000 undefined | -55.8 M undefined | -54.9 M undefined |
| 2009 | 64.4 M undefined | -5.9 M undefined | -6.6 M undefined |
| 2008 | 15 M undefined | -44 M undefined | -39.4 M undefined |
| 2007 | 1.8 M undefined | -45.8 M undefined | -41.5 M undefined |
| 2006 | 0 undefined | -46.9 M undefined | -65.9 M undefined |
| 2005 | 0 undefined | -20.8 M undefined | -20.1 M undefined |
| 2004 | 0 undefined | -8.5 M undefined | -8.9 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 0 USD | -8.5 M USD | -8.9 M USD |
| 2005 | 0 USD | -20.8 M USD | -20.1 M USD |
| 2006 | 0 USD | -46.9 M USD | -65.9 M USD |
| 2007 | 1.8 M USD | -45.8 M USD | -41.5 M USD |
| 2008 | 15 M USD | -44 M USD | -39.4 M USD |
| 2009 | 64.4 M USD | -5.9 M USD | -6.6 M USD |
| 2010 | 900,000 USD | -55.8 M USD | -54.9 M USD |
| 2011 | 21.4 M USD | -50.9 M USD | -44.4 M USD |
| 2012 | 18.4 M USD | -52.9 M USD | -48.8 M USD |
| 2013 | 400,000 USD | -61.7 M USD | -59.6 M USD |
| 2014 | 1.2 M USD | -68.8 M USD | -68.9 M USD |
| 2015 | 0 USD | -130.4 M USD | -132.1 M USD |
| 2016 | 5 M USD | -181.8 M USD | -200 M USD |
| 2017 | 36.9 M USD | 23.4 M USD | -284 M USD |
| 2018 | 91.2 M USD | -328.8 M USD | -349 M USD |
| 2019 | 182.2 M USD | -304.1 M USD | -356.4 M USD |
| 2020 | 260.9 M USD | -247 M USD | -276.9 M USD |
| 2021 | 305.5 M USD | -206.4 M USD | -250.5 M USD |
| 2022 | 329.2 M USD | -205.5 M USD | -236.6 M USD |
| 2023 | 399.36 M USD | -76.08 M USD | -151.58 M USD |
| 2024e | 520.38 M USD | -13.69 M USD | -63.75 M USD |
| 2025e | 655.7 M USD | 110.55 M USD | 72.85 M USD |
| 2026e | 866.27 M USD | 273.53 M USD | 229.61 M USD |
| 2027e | 1.14 B USD | 567.27 M USD | 462.25 M USD |
| 2028e | 1.37 B USD | 771.43 M USD | 655.61 M USD |
| 2029e | 1.56 B USD | 749.43 M USD | 731.14 M USD |
| 2030e | 1.28 B USD | 829.46 M USD | 664.67 M USD |
Amicus Therapeutics stock margins US03152W1099 · A0MSMZ
The Amicus Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amicus Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amicus Therapeutics.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Amicus Therapeutics's sales revenue. A higher gross margin percentage indicates that the Amicus Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Amicus Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Amicus Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Amicus Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Amicus Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Amicus Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Amicus Therapeutics Margin History
| Amicus Therapeutics Gross margin | Amicus Therapeutics Profit margin | Amicus Therapeutics EBIT margin | Amicus Therapeutics Profit margin |
|---|---|---|---|
| 2030e | 90.65 % | 64.55 % | 51.73 % |
| 2029e | 90.65 % | 47.98 % | 46.81 % |
| 2028e | 90.65 % | 56.23 % | 47.78 % |
| 2027e | 90.65 % | 49.94 % | 40.69 % |
| 2026e | 90.65 % | 31.58 % | 26.51 % |
| 2025e | 90.65 % | 16.86 % | 11.11 % |
| 2024e | 90.65 % | -2.63 % | -12.25 % |
| 2023 | 90.65 % | -19.05 % | -37.96 % |
| 2022 | 88.27 % | -62.42 % | -71.87 % |
| 2021 | 88.71 % | -67.56 % | -82 % |
| 2020 | 88.08 % | -94.67 % | -106.13 % |
| 2019 | 87.98 % | -166.9 % | -195.61 % |
| 2018 | 84.21 % | -360.53 % | -382.68 % |
| 2017 | 83.2 % | 63.41 % | -769.65 % |
| 2016 | 82 % | -3,636 % | -4,000 % |
| 2015 | 90.65 % | 0 % | 0 % |
| 2014 | 90.65 % | -5,733.33 % | -5,741.67 % |
| 2013 | 90.65 % | -15,425 % | -14,900 % |
| 2012 | 90.65 % | -287.5 % | -265.22 % |
| 2011 | 90.65 % | -237.85 % | -207.48 % |
| 2010 | 90.65 % | -6,200 % | -6,100 % |
| 2009 | 90.65 % | -9.16 % | -10.25 % |
| 2008 | 90.65 % | -293.33 % | -262.67 % |
| 2007 | 90.65 % | -2,544.44 % | -2,305.56 % |
| 2006 | 90.65 % | 0 % | 0 % |
| 2005 | 90.65 % | 0 % | 0 % |
| 2004 | 90.65 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 90.65 % | 0 % | 0 % |
| 2005 | 90.65 % | 0 % | 0 % |
| 2006 | 90.65 % | 0 % | 0 % |
| 2007 | 90.65 % | -2,544.44 % | -2,305.56 % |
| 2008 | 90.65 % | -293.33 % | -262.67 % |
| 2009 | 90.65 % | -9.16 % | -10.25 % |
| 2010 | 90.65 % | -6,200 % | -6,100 % |
| 2011 | 90.65 % | -237.85 % | -207.48 % |
| 2012 | 90.65 % | -287.5 % | -265.22 % |
| 2013 | 90.65 % | -15,425 % | -14,900 % |
| 2014 | 90.65 % | -5,733.33 % | -5,741.67 % |
| 2015 | 90.65 % | 0 % | 0 % |
| 2016 | 82 % | -3,636 % | -4,000 % |
| 2017 | 83.2 % | 63.41 % | -769.65 % |
| 2018 | 84.21 % | -360.53 % | -382.68 % |
| 2019 | 87.98 % | -166.9 % | -195.61 % |
| 2020 | 88.08 % | -94.67 % | -106.13 % |
| 2021 | 88.71 % | -67.56 % | -82 % |
| 2022 | 88.27 % | -62.42 % | -71.87 % |
| 2023 | 90.65 % | -19.05 % | -37.96 % |
| 2024e | 90.65 % | -2.63 % | -12.25 % |
| 2025e | 90.65 % | 16.86 % | 11.11 % |
| 2026e | 90.65 % | 31.58 % | 26.51 % |
| 2027e | 90.65 % | 49.94 % | 40.69 % |
| 2028e | 90.65 % | 56.23 % | 47.78 % |
| 2029e | 90.65 % | 47.98 % | 46.81 % |
| 2030e | 90.65 % | 64.55 % | 51.73 % |
Amicus Therapeutics Aktienanalyse
What does Amicus Therapeutics do?
Amicus Therapeutics Inc. is a biopharmaceutical company specializing in the development of drugs for the treatment of rare diseases. The company was founded in 2002 and is headquartered in Cranbury, New Jersey. Amicus Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Amicus Therapeutics's Sales Figures
The sales figures of Amicus Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Amicus Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Amicus Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Amicus Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Amicus Therapeutics Stock
How much was the turnover of the company Amicus Therapeutics compared to the previous year?
The revenue of Amicus Therapeutics has increased by 30.3% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Amicus Therapeutics?
The revenue of Amicus Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Amicus Therapeutics measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Amicus Therapeutics so important for investors?
The revenue of Amicus Therapeutics is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Amicus Therapeutics pay?
Over the past 12 months, Amicus Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amicus Therapeutics is expected to pay a dividend of 0 USD.
What is the dividend yield of Amicus Therapeutics?
The current dividend yield of Amicus Therapeutics is .
When does Amicus Therapeutics pay dividends?
Amicus Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Amicus Therapeutics?
Amicus Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Amicus Therapeutics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Amicus Therapeutics located?
Amicus Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Amicus Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Amicus Therapeutics from 6/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/13/2024.
When did Amicus Therapeutics pay the last dividend?
The last dividend was paid out on 6/13/2024.
What was the dividend of Amicus Therapeutics in the year 2023?
In the year 2023, Amicus Therapeutics distributed 0 USD as dividends.
In which currency does Amicus Therapeutics pay out the dividend?
The dividends of Amicus Therapeutics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Amicus Therapeutics stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Amicus Therapeutics
Our stock analysis for Amicus Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amicus Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Amicus Therapeutics Revenue
- Amicus Therapeutics Net Income
- Amicus Therapeutics P/E
- Amicus Therapeutics P/S
- Amicus Therapeutics EBIT
- Amicus Therapeutics Dividend
- Amicus Therapeutics Stocks
- Amicus Therapeutics Market capitalization
- Amicus Therapeutics Debt
- Amicus Therapeutics Liabilities
- Amicus Therapeutics Equity
- Amicus Therapeutics AAQS
- Amicus Therapeutics Employees
- Amicus Therapeutics ROE
- Amicus Therapeutics ROA
- Amicus Therapeutics ROCE
